Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Nanjing University of Chinese Medicine · Nanjing General Hospital of Nanjing Military Command · +43 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
652
total citations
- FWCI
- 122.11
- Percentile
- 100%
- References
- 47
Citations per year
Authors
136- SQShukui QinCorresponding
Nanjing University of Chinese Medicine, Nanjing General Hospital of Nanjing Military Command, Nanjing Medical University
- SLStephen L. Chan
Chinese University of Hong Kong
- SGShanzhi Gu
Hunan Cancer Hospital
- YBYuxian Bai
Harbin Medical University
- ZRZhenggang Ren
Fudan University, Zhongshan Hospital
Topics & keywords
Topics
Keywords
- Sorafenib
- Medicine
- Apatinib
- Hepatocellular carcinoma
- Internal medicine
- Oncology
- Population
- Interim analysis
No related works found for this paper.